These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24216565)

  • 1. U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer.
    Saif MW
    JOP; 2013 Nov; 14(6):686-8. PubMed ID: 24216565
    [No Abstract]   [Full Text] [Related]  

  • 2. First line therapy for metastatic pancreatic cancer.
    Jarboe J; Saif MW
    JOP; 2013 Jul; 14(4):340-3. PubMed ID: 23846923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis.
    Reni M; Wan Y; Solem C; Whiting S; Ji X; Botteman M
    J Med Econ; 2014 May; 17(5):338-46. PubMed ID: 24654922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
    Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of metastatic pancreatic adenocarcinoma: a review.
    Thota R; Pauff JM; Berlin JD
    Oncology (Williston Park); 2014 Jan; 28(1):70-4. PubMed ID: 24683721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
    Von Hoff DD; Ramanathan RK; Borad MJ; Laheru DA; Smith LS; Wood TE; Korn RL; Desai N; Trieu V; Iglesias JL; Zhang H; Soon-Shiong P; Shi T; Rajeshkumar NV; Maitra A; Hidalgo M
    J Clin Oncol; 2011 Dec; 29(34):4548-54. PubMed ID: 21969517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
    Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J;
    Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approves Pembrolizumab + Chemotherapy Combination for Locally Recurrent Unresectable or Metastatic TNBC.
    Slater H
    Oncology (Williston Park); 2020 Dec; 34(12):547. PubMed ID: 33395495
    [No Abstract]   [Full Text] [Related]  

  • 9. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
    O'Hara MH; O'Reilly EM; Varadhachary G; Wolff RA; Wainberg ZA; Ko AH; Fisher G; Rahma O; Lyman JP; Cabanski CR; Mick R; Gherardini PF; Kitch LJ; Xu J; Samuel T; Karakunnel J; Fairchild J; Bucktrout S; LaVallee TM; Selinsky C; Till JE; Carpenter EL; Alanio C; Byrne KT; Chen RO; Trifan OC; Dugan U; Horak C; Hubbard-Lucey VM; Wherry EJ; Ibrahim R; Vonderheide RH
    Lancet Oncol; 2021 Jan; 22(1):118-131. PubMed ID: 33387490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study.
    Kunzmann V; Ramanathan RK; Goldstein D; Liu H; Ferrara S; Lu B; Renschler MF; Von Hoff DD
    Pancreas; 2017 Feb; 46(2):203-208. PubMed ID: 27841795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
    Cho IR; Kang H; Jo JH; Lee HS; Chung MJ; Park JY; Park SW; Song SY; Chung JB; An C; Park MS; Jung SY; Bang S
    Semin Oncol; 2017 Dec; 44(6):420-427. PubMed ID: 29935903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
    Abrams TA; Meyer G; Meyerhardt JA; Wolpin BM; Schrag D; Fuchs CS
    Oncologist; 2017 Aug; 22(8):925-933. PubMed ID: 28476943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer.
    Moreno-Aspitia A; Perez EA
    Clin Breast Cancer; 2005 Oct; 6(4):361-4. PubMed ID: 16277889
    [No Abstract]   [Full Text] [Related]  

  • 14. [Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use].
    Ferris Villanueva E; Martínez Penella M; Cerezuela Fuentes P; Guerrero Bautista R; García Márquez A; Mira Sirvent Mdel C
    Farm Hosp; 2015 May; 39(3):181-5. PubMed ID: 26005895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial.
    Young R; Mainwaring P; Clingan P; Parnis FX; Asghari G; Beale P; Aly A; Botteman M; Romano A; Ferrara S; Margunato-Debay S; Harris M
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e325-e331. PubMed ID: 29932294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term progression-free survival in a metastatic pancreatic cancer patient treated with first-line nab-paclitaxel and gemcitabine.
    Boeck S; Haas M; Kruger S; Heinemann V
    In Vivo; 2014; 28(6):1189-92. PubMed ID: 25398821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
    Fernández A; Salgado M; García A; Buxò E; Vera R; Adeva J; Jiménez-Fonseca P; Quintero G; Llorca C; Cañabate M; López LJ; Muñoz A; Ramírez P; González P; López C; Reboredo M; Gallardo E; Sanchez-Cánovas M; Gallego J; Guillén C; Ruiz-Miravet N; Navarro-Pérez V; De la Cámara J; Alés-Díaz I; Pazo-Cid RA; Carmona-Bayonas A
    BMC Cancer; 2018 Nov; 18(1):1185. PubMed ID: 30497432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stromal depletion goes on trial in pancreatic cancer.
    Garber K
    J Natl Cancer Inst; 2010 Apr; 102(7):448-50. PubMed ID: 20339135
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nab-paclitaxel: Results of a retrospective analysis.
    Montes AF; Villarroel PG; Ayerbes MV; Gómez JC; Aldana GQ; Tuñas LV; Fernández MS; Fernández MJ
    J Cancer Res Ther; 2017; 13(2):240-245. PubMed ID: 28643741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer from routine clinical practice.
    Vogel A; Pelzer U; Salah-Eddin AB; Köster W
    In Vivo; 2014; 28(6):1135-40. PubMed ID: 25398812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.